These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1118 related articles for article (PubMed ID: 39138146)

  • 1. Therapeutic advances of targeting receptor tyrosine kinases in cancer.
    Tomuleasa C; Tigu AB; Munteanu R; Moldovan CS; Kegyes D; Onaciu A; Gulei D; Ghiaur G; Einsele H; Croce CM
    Signal Transduct Target Ther; 2024 Aug; 9(1):201. PubMed ID: 39138146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
    Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
    Ghosh S; Marrocco I; Yarden Y
    Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
    Hojjat-Farsangi M
    Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
    Camorani S; Crescenzi E; Fedele M; Cerchia L
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor tyrosine kinases: from biology to pathology.
    Choura M; Rebaï A
    J Recept Signal Transduct Res; 2011 Dec; 31(6):387-94. PubMed ID: 22040163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches.
    Saraon P; Pathmanathan S; Snider J; Lyakisheva A; Wong V; Stagljar I
    Oncogene; 2021 Jun; 40(24):4079-4093. PubMed ID: 34079087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between DNA repair and RTK-mediated signaling pathways.
    Chabot T; Cheraud Y; Fleury F
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188495. PubMed ID: 33346130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Axl and Mer kinases in cancer.
    Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
    Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.
    Huang XL; Khan MI; Wang J; Ali R; Ali SW; Zahra QU; Kazmi A; Lolai A; Huang YL; Hussain A; Bilal M; Li F; Qiu B
    Int J Biol Macromol; 2021 Jun; 180():739-752. PubMed ID: 33737188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic concepts of cancer genetics and receptor tyrosine kinase inhibition for pharmacists. A narrative review.
    Orrico KB
    J Oncol Pharm Pract; 2023 Jul; 29(5):1187-1195. PubMed ID: 36734129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
    Tolmachev V; Stone-Elander S; Orlova A
    Lancet Oncol; 2010 Oct; 11(10):992-1000. PubMed ID: 20667780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RTKs in pathobiology of head and neck cancers.
    Nadhan R; Srinivas P; Pillai MR
    Adv Cancer Res; 2020; 147():319-373. PubMed ID: 32593405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mislocalisation of Activated Receptor Tyrosine Kinases - Challenges for Cancer Therapy.
    Schmidt-Arras D; Böhmer FD
    Trends Mol Med; 2020 Sep; 26(9):833-847. PubMed ID: 32593582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
    Montor WR; Salas AROSE; Melo FHM
    Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.
    Niederst MJ; Engelman JA
    Sci Signal; 2013 Sep; 6(294):re6. PubMed ID: 24065147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of receptor tyrosine kinase activation in cancer.
    Du Z; Lovly CM
    Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
    Kleczko EK; Heasley LE
    Mol Cancer; 2018 Feb; 17(1):60. PubMed ID: 29458371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.